Biocytics

01/30/2026

Our very own founder and president, Dr. John Powderly, advocates for a paradigm shift towards personalized medicine at the point of care, enabled by openEHR to overcome data silos and inefficiencies in cancer research. The goal is to ultimately improve patient access, affordability, and treatment outcomes by integrating regulatory data standards into openEHR.

Check out the full video at

Dr John Powderly (Carolina BioOncology Institute & BioCytics Human Applications Lab) presenting at openEHR's EHRCON25 in Barcelona - 'Embedding phase 1 cance...

01/25/2026

At BioCytics, collaboration is essential to advancing the future of cancer diagnostics and cell based innovation.

We recently collaborated with Kidod Science and Therapeutics to explore the potential of saliva based technologies for cancer detection and multi cancer early detection research. This work reflects our commitment to evaluating emerging diagnostic approaches and partnering with innovators to expand the possibilities of early cancer detection and advance cancer research.

Through strategic scientific partnerships, BioCytics continues to explore novel technologies that support translational research and the future of precision oncology. We welcome opportunities to collaborate with researchers and organizations who share our mission to push cancer science forward - reach out to learn more!

01/23/2026

Innovation at BioCytics is driven by continuous learning and technology evaluation. We recently welcomed Cytiva for an on site lunch and learn focused on the Sepax system's BeadWash application and Sefia Select magnetic selection platform for cell therapy manufacturing.

These discussions support our efforts to optimize cell processing workflows and evaluate tools that strengthen our autologous cell therapy development pipeline. We value industry partnerships that help advance efficient and scalable solutions.

12/27/2025

🎄 Wishing our partners, collaborators, and scientific community a peaceful holiday season and an exciting start to 2026.

🚀 BioCytics 2025: Year in Review
• Progress in autologous cell therapy development
• Expansion of biobank, biospecimen sourcing, and R&D capabilities
• Strengthened collaborations with biotech, academic, and clinical teams
• Continued growth of our technology platform
• FDA INTERACT meeting for BCyIF1 completed
• Celebrated 20-year anniversary

Thank you for supporting our mission to accelerate next-generation cell therapies. Here’s to a groundbreaking new year!

12/22/2025

During SITC 2025, our Founder and CEO, Dr. John Powderly, had the opportunity to meet with Dr. Peter Marks, MD, PhD, where they connected over their shared passion for advancing oncology research. It was an honor to discuss the future of immune cell therapies manufactured at the point of care, an area where both BioCytics and Carolina BioOncology Institute remain deeply committed to driving innovation.

We also extend our congratulations to Dr. Marks on receiving the SITC 2025 Innovation Award in recognition of his impactful contributions to the field of immunotherapy.

12/19/2025

🌍 In October, our IT team attended EHRCon 2025 in Barcelona, where global experts explored the evolving world of electronic health records (EHRs), artificial intelligence (AI), and open standards.

John Powderly II, MD, representing Carolina BioOncology Institute and BioCytics, presented how openEHR enables the seamless integration of electronic data capture, laboratory information management systems (LIMS), clinical trial management, and patient EHRs into a unified information ecosystem. This model propels precision medicine forward and lays the foundation for Real-Time Adaptive Clinical Trials, a transformative approach that uses individual patient clinical evidence to continuously improve treatment outcomes for all.

Collaboration, standardization, and innovation remain at the heart of turning clinical data into actionable insights for better patient care.

12/15/2025

As we reflect on this year’s meetings and conferences, we’re proud to highlight our August participation at the 2025 Cell Manufacturing Technologies (CMaT) Summit, a collaborative event designed to connect academic researchers with leaders across the biotech industry.

Our team members Dr. Gaby Lizana-Vasquez and William Paing served as poster judges, reviewing innovative student research and emerging technologies coming out of academic labs. William also contributed as a panelist, offering insight into the current biotech landscape, industry challenges, and the future of cell therapy manufacturing.

We’re excited to continue supporting and mentoring the next generation of biotech innovators. ✨

12/11/2025

Have you listened to TIL Talks yet? TIL Talks delivers conversations with leaders and patients shaping the future of cell and gene therapy.

In episode 19 (released October 29), Chris White and Dr. John Powderly return to discuss the rapidly evolving world of digital health in oncology. They unpack challenges with Electronic Health Record systems, the importance of standardized clinical data, and the need to empower patients with access to their own health information. This episode also explores the future of clinical trials, the role of AI, and innovations that will drive earlier cancer detection and improved outcomes.

At BioCytics, we explore how BioDICE technology empowers point-of-care immune cell therapy and next-generation clinical trial design. This episode is a must-listen for anyone passionate about biotech innovation and translational research.

11/21/2025

As Breast Cancer Awareness Month comes to a close, we want to highlight that awareness and research must continue every day of the year. 💗

🔬 Did you know?
• About 30% of early-stage breast cancers may later progress to metastatic disease.
• More than 150,000 people in the U.S. are living with metastatic breast cancer.
• While it is not currently curable, treatment advances are helping patients live longer, fuller lives.

At Carolina BioOncology Institute, we are dedicated to advancing research that brings new hope and options to patients through clinical trials and innovation in cancer care.

Awareness does not end in October, rather it continues with every patient, every day. 💫

11/21/2025

Biocytics Inc announces the successful completion of a productive FDA INTERACT meeting supporting our plans to manufacture autologous immune cell therapies at the point of care.

This initial regulatory engagement validates the scientific promise of our immuno-oncology platform and our lead investigational fraction, BioCytics Immune Fraction #1 (BCyIF-1). The FDA’s feedback reinforces our continued progress toward an IND submission and first-in-human clinical trials targeted for 2027, advancing our mission to bring innovative cell therapies to patients with solid tumors.

Learn more at www.biocytics.com or read the full announcement at PR Newswire at www.bit.ly/4ibp5of.

11/15/2025

Big thank you to the students from Davidson College for visiting! We loved sharing our work, our mission, and the exciting career paths ahead in biotech and in immuno-oncology cancer research.

09/15/2025

Biocytics and Carolina BioOncology Institute are proud to sponsor the Biomedical Sciences Symposium hosted by UNC Charlotte’s Center for Biomedical Engineering and Science in collaboration with the North Carolina Biotechnology Center.

This event unites breakthrough discoveries, translational research, and new collaborations in biomedical sciences. We are honored to support a forum that further advances science, fosters partnerships, and shapes the future of biomedical research!🔬